Precision Medicine & Society Conference
Precision Medicine & Society: International Perspectives
May 7, 2020
Precision Medicine & Society: International Perspectives Virtual Conference
May 7, 2020
Each talk will be 20 minutes and each panel will conclude with a 30 minute discussion and Q&A
Please find the links to each panel discussion below. These can also be found on our video library here.
Panel: Impact on Global Health Disparities and Public Health moderated by Gil Eyal
Donna Dickenson, University of London
Sandro Galea, Boston University
Panel: Rolling Out Precision Medicine Around the World moderated by Maya Sabatello
China – Haidan Chen, Peking University
Denmark – Katharina Eva O’Cathaoir, University of Copenhagen
Brazil – Jorge Alberto Bernstein Iriart, Instituto de Saúde Coletiva, Universidade Federal da Bahia
Ethics – Barbara Prainsack, University of Vienna
Regulation – Adrian Thorogood, McGill University
Economics – Patricia Danzon, The Wharton School, University of Pennsylvania
Reflections on Precision Medicine & Society from an International Perspective, Amy Zhou
The first Columbia University Precision Medicine & Society Symposium: “Precision Medicine: Its Impact on Patients, Providers, and Public Health.” The Precision Medicine & Society Program is an integral part of Columbia’s Precision Medicine Initiative (CPMI), which grew out of conversations between President Lee Bollinger and Dr. Roy Vagelos.
We heard from physicians, social scientists, bio-ethicists, journalists, science policy leaders, economists, and humanists who are thinking hard about the social, political, and economic consequences of precision medicine. As cutting-edge basic research is translated into clinical applications, and as advances in the analysis of large datasets come to inform public health policy, there is an urgent need to consider the potential implications for patients, the physician-patient relationship, the economic arrangements underlying the provision of health care, and the social contract between citizens and public health institutions.
The Precision Medicine & Society Program—a University-wide collaboration of disciplines at Columbia University—was created to jumpstart academic discussion and research about these issues. It brings together biomedical and public health researchers, clinicians and bio-ethicists working at the Columbia University Irving Medical Center with social scientists, legal scholars and humanists in the Faculty of Arts & Sciences and the Law School.
While advances in diagnosis, targeting, personalization and prediction remain for the most part promissory, there is little doubt that over the long term they will transform the practice of medicine, the meaning of disease, and the nature of patienthood. Precision medicine will alter the division of labor among clinicians, information scientists, and researchers, and rechannel the flow of personal data from patients to doctors, healthcare organizations and for-profit entities. This will require fundamental adaptations in medical education, in the relations between doctors and patients, in legal and regulatory frameworks, and in arrangements for payment and reimbursement. We believe that Columbia University, as a leading teaching and research institution, is ideally positioned to lead the conversation on these issues.
Our thanks to President Bollinger, the CPMI, and, especially, to its director, Tom Maniatis, for supporting the Precision Medicine & Society Program.
Paul S. Appelbaum, MD, Elizabeth K. Dollard Professor of Psychiatry, Medicine and Law
Gil Eyal, PhD, Professor of Sociology
Co-Directors of the Columbia Precision Medicine and Society Program
SPEAKERS:
Harold Varmus, MD, Weill Cornell Medical College
What “Precision Medicine” Means for a Biomedical Scientist
Paul Starr, PhD, Princeton University
The Social Challenges of Precision Medicine
Naveen Rao, MD, Rockefeller Foundation
Applying “Precision” to Community Health
Eric Juengst, PhD, University of North Carolina-Chapel Hill School of Medicine
Ethical Challenges in Precision Approaches to Infectious Disease: The Case of Phylogenetic Tuberculosis Sequencing
Sophie Day, PhD, Goldsmiths, University of London, and Imperial College London
Historicizing Precision Medicine for Breast Cancer by Reference to Previous Service Developments in a London (UK) Hospital Group
Catherine Bourgain, PhD, French National Institute for Health and Medical Research; Cermes3; CNRS, EHESS, Inserm, and University Paris Paris-Est University
Making Tumor Genetics Doable in the Clinic. Insights from a French Case Study
Ashveen Peerbaye, PhD, Laboratoire Interdisciplinaire Sciences Innovations Sociétés (LISIS, CNRS)
Making Tumor Genetics Doable in the Clinic. Insights from a French Case Study
Tanya Stivers, PhD, UCLA
What Would Precision Medicine in the Clinic Look Like? Some Lessons from the Return of Exome Sequencing Results
Antonio Regaldo, MIT Technology Review
Precision Gone Mad: A Reporter’s Adventures with Polygenic IQ Scores, Pay-to-Play Gene Therapy, and CRISPR Babies
Jonathan LaPoo, MD, CBS News; NYU Langone Medical Center
Reporting on Precision Medicine for CBS News
Jeremy Greene, MD, PhD, Johns Hopkins School of Medicine
The Computer in the Clinic: Past Futures of Precision Medicine
Matt Might, PhD, University of Alabama, Birmingham
The Algorithm for Precision Medicine
Dana Goldman, PhD, University of Southern California
The Economics of Personalized Medicine and the Value of Improved Diagnostics
Frank Lichtenberg, PhD, Columbia University
How Many Life Years Have New Drugs Saved? A 3-way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000–2013
Christina Cogdell, PhD, University of California, Davis
Designing Complexity: Pushing the Limits of Big Data
Peter Lloyd Jones, PhD, Lancaster University, UK
Imagining the Future of PM: Design & Science for Next-Gen Cell-/Sel-Fies
Jenny Reardon, PhD, University of California, Santa Cruz
Can Precision Medicine Be Just?
See our video library for conference talks here.